Clinical Trial Update: A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage [Phase 2]

View source ↗

Summary

Phase II randomized trial comparing cisplatin/etoposide with either Hedgehog inhibitor GDC-0449 or IGF-1R monoclonal antibody IMC-A12 in extensive-stage or recu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• GDC-0449 (vismodegib)
• IMC-A12 (cixutumumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extensive Stage Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2015-07-29